SWOG clinical trial number
CTSU/EA2192

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Open
Phase
II
Abbreviated Title
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Activated
04/29/2021

Research committees

Gastrointestinal Cancer

Treatment

Olaparib

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unity (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA2201
SWOG Clinical Trial Number
CTSU/EA2197

Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

Research Committee(s)
Gastrointestinal Cancer
Activated
12/22/2020
Open
Phase
II-III